Overall study design and governance
HCM
MAY, ADVERSE EVENT, HYPERTROPHIC CARDIOMYOPATHY
The Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyopathy (TEMPEST) is a multicentre, double-blind, parallel group, 1:1 randomised, placebo-controlled phase II clinical trial designed to evaluate the efficacy and mechanism of action of trientine in patients with HCM. The overall study design is summarised in TEMPEST trial design. §May be performed at visit 1 or visit 2 but must be done before randomisation. AE, adverse event; BP, blood pressure; CMR, cardiovascular magnetic resonance; IMP, investigational medicinal product; 